Aisling Capital is an investment firm focused on health-related innovations, particularly in biotechnology and biopharmaceuticals. The firm typically invests in Series A to Series E rounds, with a strong emphasis on later-stage investments such as Series B and Series C. Aisling Capital targets companies developing novel therapeutics for disease diagnosis, prevention, and treatment, leveraging advancements in genomics and biotechnology.